Nicorandil to Prevent Contrast-Associated Kidney Injury in High-Risk PCI
Circulation: Cardiovascular Interventions · 2026
DOI: 10.1161/circinterventions.126.016928 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation: Cardiovascular Interventions, 2026. Verfasst von Minqi Liao und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Dongguan People's Hospital (The Tenth Affiliated Hospital of Southern Medical University), China (M.L., W.Z., W.W., Y. Yang…. Hauptthemen laut MEDLINE: Nicorandil, Acute Kidney Injury, Percutaneous Coronary Intervention, Contrast Media. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Patients with renal dysfunction remain at high risk for contrast-associated acute kidney injury despite standard peri-procedural volume administration. This study aims to investigate whether peri-procedural oral nicorandil provides additional protection in this population, and to evaluate its potential dose-response relationship. METHODS: We conducted a prospective, multicenter, randomized controlled trial enrolling patients with renal dysfunction undergoing percutaneous coronary intervention. Participants were randomized into 3 groups, including a high-dose nicorandil group (30 mg/d, 10 mg 3× daily), a conventional-dose nicorandil group (15 mg/d, 5 mg 3× daily), and a saline hydration-only control group. The primary end point was the incidence of contrast-associated acute kidney injury. Secondary end points included changes in serum creatinine, blood urea nitrogen, CysC (cystatin C), and CRP (C-reactive protein). RESULTS: A total of 585 patients were recruited and randomized. The incidence of contrast-associated acute kidney injury was significantly lower in both nicorandil groups, with 19.8% (39/197) in the control group, compared with 10.9% (21/193) in the conventional-dose group and 8.7% (17/195) in the high-dose group ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Dongguan People's Hospital (The Tenth Affiliated Hospital of Southern Medical University), China (M.L., W.Z., W.W., Y. Yang, Y. Yao, G.Z., Zhihao Wu, X.Z., B.W., G.L., Z.L., Zhanyang Wei, J.L.,…
- Department of Cardiovascular and Neurology, Dongguan Xiegang Hospital, China (Zekui Wu).
- Department of Cardiology, Taishan People's Hospital, Jiangmen, China (Y.C.).
- Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (B.Z.).
ORCID-Profile: Minqi Liao, Zhihao Wu, Suxia Guo
Zitieren
APA
Liao, M., Zhou, W., Wang, W., Yang, Y., Yao, Y., Zhou, G., Wu, Z., Zhang, X., Wei, B., Liang, G., Li, Z., Wei, Z., Lu, J., Wu, Z., Wang, Y., Lin, A., Chen, Y., Zhang, B., & Guo, S. (2026). Nicorandil to Prevent Contrast-Associated Kidney Injury in High-Risk PCI. Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.126.016928
Vancouver
Liao M, Zhou W, Wang W, Yang Y, Yao Y, Zhou G, et al. Nicorandil to Prevent Contrast-Associated Kidney Injury in High-Risk PCI. Circulation: Cardiovascular Interventions. 2026. doi:10.1161/circinterventions.126.016928
BibTeX
@article{Liao2026,
author = {Liao, Minqi and Zhou, Weiliang and Wang, Wenbin and Yang, Yanhua and Yao, Yongzhao and Zhou, Guoxiang and Wu, Zhihao and Zhang, Xiaoming and Wei, Bailiang and Liang, Guangzhu and Li, Zheng and Wei, Zhanyang and Lu, Jiongbin and Wu, Zekui and Wang, Yanna and Lin, Ailing and Chen, Yan and Zhang, Bin and Guo, Suxia},
title = {Nicorandil to Prevent Contrast-Associated Kidney Injury in High-Risk PCI},
journal = {Circulation: Cardiovascular Interventions},
year = {2026},
doi = {10.1161/circinterventions.126.016928}
}
EUVIMED